Seresco S.A. (BME:SCO)

Verve Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Revenue	30.7	30.89	26.43	25.46	24.66
Revenue Growth (YoY)	-0.61%	16.88%	3.83%	3.21%	16.29%
Cost of Revenue	3.6	5.11	3	2.94	4.32
Gross Profit	27.11	25.79	23.43	22.52	20.34
Selling, General & Admin	24.69	23.52	21.28	19.84	18.71
Other Operating Expenses	0.12	0.11	0.06	0.55	0.31
Operating Expenses	25.92	24.08	21.69	20.65	19.27
Operating Income	1.19	1.7	1.74	1.87	1.07
Interest & Investment Income	0.03	0.01	0.03	0.07	0.01
Other Non Operating Income (Expenses)	-0.51	-0.13	-0.15	-0.16	-0.08
Pretax Income	0.7	1.58	1.62	1.77	1
Income Tax Expense	-0.21	0.29	0.3	0.41	0.18
Earnings From Continuing Operations	0.92	1.29	1.32	1.36	0.83
Net Income	0.92	1.29	1.32	1.36	0.83
Net Income Growth	-28.75%	-2.29%	-3.00%	64.75%	67.88%
Gross Margin	88.29%	83.47%	88.64%	88.45%	82.47%
Operating Margin	3.86%	5.51%	6.58%	7.33%	4.34%
Profit Margin	2.99%	4.17%	4.99%	5.34%	3.35%
EBITDA	2.3	2.15	2.09	2.13	1.32
EBITDA Margin	7.48%	6.97%	7.90%	8.38%	5.35%
EBIT	1.19	1.7	1.74	1.87	1.07
EBIT Margin	3.86%	5.51%	6.58%	7.33%	4.34%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.